Pathophysiology and prevention of sudden cardiac death

Canadian Journal of Physiology and Pharmacology

Volumn 94, Issue 3, 2015, Pages 237-244

  Goyal, Vineet ^a,b   Jassal, Davinder S ^a,b   Dhalla, Naranjan S ^a,b  

^a ST BONIFACE GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Arrhythmias; Coronary artery disease; Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Sudden cardiac death

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL;

CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; HEART ARRHYTHMIA; HEART RIGHT VENTRICLE DYSPLASIA; HIGH RISK POPULATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SUDDEN CARDIAC DEATH; ANIMAL; DEATH, SUDDEN, CARDIAC; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; PATHOLOGY; PROCEDURES; RISK FACTOR;

ANIMALS; DEATH, SUDDEN, CARDIAC; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HUMANS; RISK FACTORS;

EID: 84959362270     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2015-0366     Document Type: Review

References (105)

1. Ackerman, M.J. 2008. Unmasking concealed long QT syndrome. Heart Rhythm, 5(1): 8–10. doi:10.1016/j.hrthm.2007.11.009.
2. Adameova, A., Abdellatif, Y., and Dhalla, N.S. 2009. Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease. Can. J. Physiol. Pharmacol. 87(7): 493–514. doi:10.1139/Y09-042.
3. Aljaroudi, W.A., Flamm, S.D., Saliba, W., Wilkoff, B.L., and Kwon, D. 2013. Role of CMR imaging in risk stratification for sudden cardiac death. JACC Cardiovasc. Imaging, 6(3): 392–406. doi:10.1016/j.jcmg.2012.11.011.
4. Angelini, A., Basso, C., Nava, A., and Thiene, G. 1996. Endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy. Am. Heart J. 132(1): 203–206. doi:10.1016/S0002-8703(96)90416-0.
5. Ardissino, D., Cavallini, C., Bramucci, E., Indolfi, C., Marzocchi, A., Manari, A., et al.; SES-SMART Investigators. 2004. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA, 292(22): 2727–2734. doi:10.1001/jama.292.22.2727.
6. Aro, A.L., and Huikuri, H.V. 2013. Electrocardiographic predictors of sudden cardiac death from a large Finnish general population cohort. J. Electrocardiol. 46(5): 434–438. doi:10.1016/j.jelectrocard.2013.06.016.
7. Awad, M.M., Calkins, H., and Judge, D.P. 2008. Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat. Clin. Pract. Cardiovasc. Med. 5(5): 258–267. doi:10.1038/ncpcardio1182.
8. Bardy, G.H., Lee, K.L., Mark, D.B., Poole, J.E., Packer, D.L., Boineau, R., et al. Sudden Cardiac Death in Heart Failure Trial Investigators. 2005. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352(3): 225–237. doi:10.1056/NEJMoa043399.
9. Basso, C., Thiene, G., Corrado, D., Angelini, A., Nava, A., and Valente, M. 1996. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation, 94(5): 983–991. doi:10.1161/01.CIR.94.5.983.
10. Bauce, B., Basso, C., Rampazzo, A., Beffagna, G., Daliento, L., Frigo, G., et al. 2005. Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. Eur. Heart J. 26(16): 1666–1675. doi:10.1093/eurheartj/ehi341.
11. Behonick, G.S., Novak, M.J., Nealley, E.W., and Baskin, S.I. 2001. Toxicology update: the cardiotoxicity of the oxidative stress metabolites of catecholamines (aminochromes). J. Appl. Toxicol. 21(Suppl. 1): S15–S22. doi:10. 1002/jat.793.
12. Berger, S., and Campbell, R.M. 2009. Sudden cardiac death in children and adolescents: introduction and overview. Pacing Clin. Electrophysiol. 32(Suppl. 2): S2–S5. doi:10.1111/j.1540-8159.2009.02378.x.
13. Bierkamp, C., McLaughlin, K.J., Schwarz, H., Huber, O., and Kemler, R. 1996. Embryonic heart and skin defects in mice lacking plakoglobin. Dev. Biol. 180(2): 780–785. doi:10.1006/dbio.1996.0346.
14. Bonow, R.O. 2015. Hypertrophic cardiomyopathy: past, present. and future. Trends Cardiovasc. Med. 25(1): 65–66. doi:10.1016/j.tcm.2014.10.012.
15. Bouska, I., Klir, P., and Markvartova, J. 2008. Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) as a cause of sudden death. Soud. Lek. 53(2): 18–20.
16. Brydon, L., Magid, K., and Steptoe, A. 2006. Platelets, coronary heart disease, and stress. Brain Behav. Immun. 20(2): 113–119. doi:10.1016/j.bbi.2005.08.002.
17. Buxton, A.E., Ellison, K.E., Kirk, M.M., Frain, B., Koo, C., Gandhi, G., et al. 2003. Primary prevention of sudden cardiac death: trials in patients with coronary artery disease. J. Interv. Card. Electrophysiol. 9(2): 203–206. doi:10.1023/A: 1026236524273.
18. Castellano, M., and Bohm, M. 1997. The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension, 29(3): 715–722. doi:10.1161/01.HYP.29.3.715.
19. Coumbe, A., Perez-Martinez, A.L., Fegan, A.W., and Hill, I.R. 1997. Arrhythmogenic right ventricular dysplasia (ARVD): an overlooked and underdiagnosed condition? Med. Sci. Law, 37(3): 262–265. doi:10.1177/002580249703700314.
20. Cruickshank, J.M. 2010. Beta blockers in hypertension. Lancet, 376(9739): 415; author reply 415-416. doi:10.1016/S0140-6736(10)61217-2.
21. Czarny, M.J., and Resar, J.R. 2014. Diagnosis and management of valvular aortic stenosis. Clin. Med. Insights Cardiol. 8(Suppl. 1): 15–24. doi:10.4137/CMC. S15716.
22. Davis, J.A., Cecchin, F., Jones, T.K., and Portman, M.A. 2001. Major coronary artery anomalies in a pediatric population: incidence and clinical importance. J. Am. Coll. Cardiol. 37(2): 593–597. doi:10.1016/S0735-1097(00)01136-0.
23. Dhalla, N.S., Temsah, R.M., and Netticadan, T. 2000. Role of oxidative stress in cardiovascular diseases. J. Hypertens. 18(6): 655–673. doi:10.1097/00004872-200018060-00002.
24. Dhalla, N.S., Adameova, A., and Kaur, M. 2010. Role of catecholamine oxidation in sudden cardiac death. Fundam. Clin. Pharmacol. 24(5): 539–546. doi:10. 1111/j.1472-8206.2010.00836.x.
25. DiNicolantonio, J.J., Fares, H., Niazi, A.K., Chatterjee, S., D’Ascenzo, F., Cerrato, E., et al. 2015. beta-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart, 2(1): e000230. doi:10.1136/openhrt-2014-000230.
26. Doval, H.C., Nul, D.R., Grancelli, H.O., Perrone, S.V., Bortman, G.R., Curiel, R., and Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). 1994. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet, 344(8921): 493–498. doi:10.1016/S0140-6736(94) 91895-3.
27. Ferreira, M., Santos-Silva, P.R., de Abreu, L.C., Valenti, V.E., Crispim, V., Imaizumi, C., et al. 2010. Sudden cardiac death athletes: a systematic review. Sports Med. Arthrosc. Rehabil. Ther. Technol. 2: 19. doi:10.1186/1758-2555-2-19.
28. Flett, A.S., Hayward, M.P., Ashworth, M.T., Hansen, M.S., Taylor, A.M., Elliott, P.M., et al. 2010. Equilibrium contrast cardiovascular magnetic resonance for the nmeasurement of diffuse myocardial fibrosis: preliminary validationinhumans. Circulation,122(2):138–144.doi:10.1161/CIRCULATIONAHA. 109.930636.
29. Francis, J., and Namboodiri, N. 2014. Update on ventricular tachyarrhythmias and related sudden cardiac death. Indian Pacing Electrophysiol. J. 14(6): 316–319.
30. Franco, E., Dias, A., Teresa, D., and Hebert, K. 2014. EKG pattern of Brugada syndrome and sudden infant death syndrome–is it time to review the diagnostic criteria? Case report and review of literature. Ann. Noninvasive Electrocardiol. 19(2): 198–202. doi:10.1111/anec.12086.
31. Freemantle, N., Cleland, J., Young, P., Mason, J., and Harrison, J. 1999. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ, 318(7200): 1730–1737. doi:10.1136/bmj.318.7200.1730.
32. Friedewald, V.E., Jr., and Spence, D.W. 1990. Sudden cardiac death associated with exercise: the risk-benefit issue. Am. J. Cardiol. 66(2): 183–188. doi:10.1016/0002-9149(90)90585-O.
33. Gaither, N.S., Rogan, K.M., Stajduhar, K., Banks, A.K., Hull, R.W., Whitsitt, T., et al. 1991. Anomalous origin and course of coronary arteries in adults: identification and improved imaging utilizing transesophageal echocardiography. Am. Heart J. 122(1): 69–75. doi:10.1016/0002-8703(91)90760-F.
34. Garcia-Gras, E., Lombardi, R., Giocondo, M.J., Willerson, J.T., Schneider, M.D., Khoury, D.S., et al. 2006. Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J. Clin. Invest. 116(7): 2012–2021. doi:10.1172/JCI27751.
35. Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 58(25): 2703–2738. doi:10.1016/j.jacc.2011.10. 825.
36. Go, A.S., Yang, J., Gurwitz, J.H., Hsu, J., Lane, K., and Platt, R. 2008. Comparative with heart failure in clinical practice. Arch. Intern. Med. 168(22): 2415–2421. doi:10.1001/archinternmed.2008.506.
37. Goldfarb, L.G., Park, K.Y., Cervenakova, L., Gorokhova, S., Lee, H.S., Vasconcelos, O., et al. 1998. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat. Genet. 19(4): 402–403. doi:10.1038/1300.
38. Gow, R. 2009. Preventing sudden cardiac death in the young: Is electrocardiogram screening the most effective means? Paediatr. Child Health, 14(3): 185–188.
39. Haft, J.I., Kranz, P.D., Albert, F.J., and Fani, K. 1972. Intravascular platelet aggregation in the heart induced by norepinephrine: Microscopic studies. Circulation, 46(4): 698–708. doi:10.1161/01.CIR.46.4.698.
40. Hammermeister, K.E., DeRouen, T.A., Murray, J.A., and Dodge, H.T. 1977. Effect of aortocoronary saphenous vein bypass grafting on death and sudden death. Comparison of nonrandomized medically and surgically treated cohorts with comparable coronary disease and left ventricular function. Am. J. Cardiol. 39(6): 925–934. doi:10.1016/S0002-9149(77)80048-9.
41. Hannan, E.L., Wu, C., Walford, G., Culliford, A.T., Gold, J.P., Smith, C.R., et al. 2008. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N. Engl. J. Med. 358(4): 331–341. doi:10.1056/NEJMoa071804.
42. Hauser, M. 2005. Congenital anomalies of the coronary arteries. Heart, 91(9): 1240–1245. doi:10.1136/hrt.2004.057299.
43. Heitzer, T., Schlinzig, T., Krohn, K., Meinertz, T., and Munzel, T. 2001. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation, 104(22): 2673–2678. doi:10. 1161/hc4601.099485.
44. Iles, L., Pfluger, H., Phrommintikul, A., Cherayath, J., Aksit, P., Gupta, S.N., et al. 2008. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J. Am. Coll. Cardiol. 52(19): 1574–1580. doi:10.1016/j.jacc.2008.06.049.
45. Iskandrian, A.S., Segal, B.L., Wasserman, L., Kimbiris, D., and Bemis, C.E. 1978. Sudden death in severe aortic stenosis following cardiac catheterization. Cathet. Cardiovasc. Diagn. 4(4): 419–425. doi:10.1002/ccd.1810040410.
46. Kasper, E.K., Agema, W.R., Hutchins, G.M., Deckers, J.W., Hare, J.M., and Baughman, K.L. 1994. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J. Am. Coll. Cardiol. 23(3): 586–590. doi:10.1016/0735-1097(94)90740-4.
47. Kong, M.H., Fonarow, G.C., Peterson, E.D., Curtis, A.B., Hernandez, A.F., Sanders, G.D., et al. 2011. Systematic review of the incidence of sudden cardiac death in the United States. J. Am. Coll. Cardiol. 57(7): 794–801. doi:10. 1016/j.jacc.2010.09.064.
48. Krexi, L., Georgiou, R., Krexi, D., and Sheppard, M.N. 2015. Sudden cardiac death with stress and restraint: The association with sudden adult death syndrome, cardiomyopathy and coronary artery disease. Med. Sci. Law. doi:10.1177/0025802414568483.
49. Kuhl, U., Pauschinger, M., Noutsias, M., Seeberg, B., Bock, T., Lassner, D., et al. 2005. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation, 111(7): 887–893. doi:10.1161/01.CIR.0000155616.07901.35.
50. Kulbertus, H.E. 1988. Ventricular arrhythmias, syncope and sudden death in aortic stenosis. Eur. Heart J. 9(Suppl. E): 51-52. doi:10.1093/eurheartj/9.suppl_E. 51.
51. Lange, R.A., and Hillis, L.D. 2003. Cardiology patient pages. Diagnostic cardiac catheterization.Circulation,107(17):e111–e113.doi:10.1161/01.CIR.0000070982. 94049.A2.
52. Lee, N.R., Park, J.H., and Rhee, K.S. 2008. Acquired long QT syndrome and sudden cardiac death due to secondary hemochromatosis with multitransfusions for severe aplastic anemia. Ann. Hematol. 87(11): 933–935. doi:10.1007/s00277-008-0507-7.
53. Lerman, A., and Zeiher, A.M. 2005. Endothelial function: cardiac events. Circulation, 111(3): 363–368. doi:10.1161/01.CIR.0000153339.27064.14.
54. Li, D., Liu, Y., Maruyama, M., Zhu, W., Chen, H., Zhang, W., et al. 2011a. Restrictive loss of plakoglobin in cardiomyocytes leads to arrhythmogenic cardiomyopathy. Hum. Mol. Genet. 20(23): 4582–4596. doi:10.1093/hmg/ddr392.
55. Li, J., Swope, D., Raess, N., Cheng, L., Muller, E.J., and Radice, G.L. 2011b. Cardiac tissue-restricted deletion of plakoglobin results in progressive cardiomyopathy and activation of {beta}-catenin signaling. Mol. Cell. Biol. 31(6): 1134–1144. doi:10.1128/MCB.01025-10.
56. Lopes, L.R., Zekavati, A., Syrris, P., Hubank, M., Giambartolomei, C., Dalageorgou, C., et al. 2013. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J. Med. Genet. 50(4): 228–239. doi:10.1136/jmedgenet-2012-101270.
57. Luk, A., Ahn, E., Soor, G.S., and Butany, J. 2009. Dilated cardiomyopathy: a review. J. Clin. Pathol. 62(3): 219–225. doi:10.1136/jcp.2008.060731.
58. Marian, A.J., Salek, L., and Lutucuta, S. 2001. Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Med. 92(6): 435–451.
59. Maron, B.J. 1997. Risk profiles and cardiovascular preparticipation screening of competitive athletes. Cardiol. Clin. 15(3): 473–483. doi:10.1016/S0733-8651(05) 70353-2.
60. Maron, B.J. 2002a. Cardiology patient pages. Hypertrophic cardiomyopathy. Circulation, 106(19): 2419–2421. doi:10.1161/01.CIR.0000034170.83171.0B.
61. Maron, B.J. 2002b. Hypertrophic cardiomyopathy: a systematic review. JAMA, 287(10): 1308–1320. doi:10.1001/jama.287.10.1308.
62. Maron, B.J. 2002c. Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Cardiol. Rev. 10(3): 173–181. doi:10.1097/00045415-200205000-00006.
63. Maron, B.J., Leon, M.B., Swain, J.A., Cannon, R.O., III, and Pelliccia, A. 1991. Prospective identification by two-dimensional echocardiography of anomalous origin of the left main coronary artery from the right sinus of Valsalva. Am. J. Cardiol. 68(1): 140–142. doi:10.1016/0002-9149(91)90732-Z.
64. Martino, T.A., Liu, P., and Sole, M.J. 1994. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ. Res. 74(2): 182–188. doi:10.1161/01.RES.74.2.182.
65. Menghetti, L., Basso, C., Nava, A., Angelini, A., and Thiene, G. 1996. Spin-echo nuclear magnetic resonance for tissue characterisation in arrhythmogenic right ventricular cardiomyopathy. Heart, 76(6): 467–470. doi:10.1136/hrt.76. 6.467.
66. Mirowski, M., Reid, P.R., Mower, M.M., Watkins, L., Gott, V.L., Schauble, J.F., et al. 1980. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N. Engl. J. Med. 303(6): 322–324. doi:10.1056/NEJM198008073030607.
67. Montgomery, J.V., Harris, K.M., Casey, S.A., Zenovich, A.G., and Maron, B.J. 2005. Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy. Am. J. Cardiol. 96(2): 270–275. doi:10.1016/j.amjcard.2005.03.058.
68. Moon, J.C., Reed, E., Sheppard, M.N., Elkington, A.G., Ho, S.Y., Burke, M., et al. 2004. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 43(12): 2260–2264. doi:10.1016/j.jacc.2004.03.035.
69. Morice, M.-C., Serruys, P.W., Sousa, J.E., Fajadet, J., Ban Hayashi, E., Perin, M., et al.; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. 2002. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346(23): 1773–1780. doi:10.1056/NEJMoa012843.
70. Morita, H., Rehm, H.L., Menesses, A., McDonough, B., Roberts, A.E., Kucherlapati, R., et al. 2008. Shared genetic causes of cardiac hypertrophy in children and adults. N. Engl. J. Med. 358(18): 1899–1908. doi:10.1056/NEJMoa075463.
71. Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Holmes, D.R., O’Shaughnessy, C., et al.; SIRIUS Investigators. 2003. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349(14): 1315–1323. doi:10.1056/NEJMoa035071.
72. Murray, B. 2012. Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C): a review of molecular and clinical literature. J. Genet. Couns. 21(4): 494–504. doi:10.1007/s10897-012-9497-7.
73. Oldfors, A., Eriksson, B.O., Kyllerman, M., Martinsson, T., and Wahlstrom, J. 1994. Dilated cardiomyopathy and the dystrophin gene: an illustrated review. Br. Heart J. 72(4): 344–348. doi:10.1136/hrt.72.4.344.
74. Postema, P.G., and Wilde, A.A. 2008. Do patients with long QT syndrome remain at risk for sudden cardiac death after 40 years of age? Nat. Clin. Pract. Cardiovasc. Med. 5(10): 602–603. doi:10.1038/ncpcardio1305.
75. Richardson, P., McKenna, W., Bristow, M., Maisch, B., Mautner, B., O’Connell, J., et al. 1996. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation, 93(5): 841–842. doi:10.1161/01.CIR.93. 5.841.
76. Roden, D.M. 2008. Clinical practice. Long-QT syndrome. N. Engl. J. Med. 358(2): 169–176. doi:10.1056/NEJMcp0706513.
77. Rollins, G. 2001. Low daily aspirin doses reduce risk of blood clots as effectively as higher doses. Rep. Med. Guidel. Outcomes Res. 12(4): 5–7.
78. Rollins, G. 2002. Aspirin therapy now recommended for people at risk for heart disease. Rep. Med. Guidel. Outcomes Res. 13(3): 1–2, 5.
79. Rona, G., Boutet, M., Huttner, I., and Peters, H. 1973. Pathogenesis of isoproterenolinduced myocardial alterations: functional and morphological correlates. Recent Adv. Stud. Cardiac Struct. Metab. 3: 507–525.
80. Ross, J., Jr. 2002. Dilated cardiomyopathy: concepts derived from gene deficient and transgenic animal models. Circ. J. 66(3): 219–224. doi:10.1253/circj.66.219.
81. Ruiz Ruiz, F.J., Gonzalez Cortijo, J., Zalba Etayo, B., Leon Cinto, C., and Sanchez Miret, J.I. 2003. Asymptomatic aortic valve stenosis and sudden death. An. Med. Interna. 20(10): 529–531.
82. Saenen, J.B., and Vrints, C.J. 2008. Molecular aspects of the congenital and acquired Long QT Syndrome: clinical implications. J. Mol. Cell. Cardiol. 44(4): 633–646. doi:10.1016/j.yjmcc.2008.01.006.
83. Sara, J.D., Eleid, M.F., Gulati, R., and Holmes, D.R., Jr. 2014. Sudden cardiac death from the perspective of coronary artery disease. Mayo Clin. Proc. 89(12): 1685–1698. doi:10.1016/j.mayocp.2014.08.022.
84. Sequeira, V., Nijenkamp, L.L., Regan, J.A., and van der Velden, J. 2014. The physiological role of cardiac cytoskeleton and its alterations in heart failure. Biochim. Biophys. Acta, 1838(2): 700–722. doi:10.1016/j.bbamem.2013.07.011.
85. Shimizu, W., and Shimomura, K. 1991. Arrhythmogenic right ventricular dysplasia (ARVD). Nihon Rinsho, 49(11): 2630–2634.
86. Singh, S.N., Fletcher, R.D., Fisher, S.G., Singh, B.N., Lewis, H.D., Deedwania, P.C., et al.; Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. 1995. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N. Engl. J. Med. 333(2): 77–82. doi:10.1056/NEJM199507133330201.
87. Spieker, L.E., Hurlimann, D., Ruschitzka, F., Corti, R., Enseleit, F., Shaw, S., et al. 2002. Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation, 105(24): 2817–2820. doi:10.1161/01.CIR. 0000021598.15895.34.
88. Spirito, P., and Maron, B.J. 1990. Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J.Am.Coll.Cardiol.15(7):1521–1526.doi:10.1016/0735-1097(90)92820-R.
89. Spirito, P., Maron, B.J., Chiarella, F., Bellotti, P., Tramarin, R., Pozzoli, M., et al. 1985. Diastolic abnormalities in patients with hypertrophic cardiomyopathy: relation to magnitude of left ventricular hypertrophy. Circulation, 72(2): 310–316. doi:10.1161/01.CIR.72.2.310.
90. Stahley, S.N., and Kowalczyk, A.P. 2015. Desmosomes in acquired disease. Cell Tissue Res. 360(3): 439–456. doi:10.1007/s00441-015-2155-2.
91. Steinfath, M., Danielsen, W., von der, Leyen, H., Mende, U., Meyer, W., Neumann, J., et al. 1992. Reduced alpha 1-and beta 2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure. Br. J. Pharmacol. 105(2): 463–469. doi:10.1111/j.1476-5381.1992.tb14276.x.
92. Stork, S., Hense, H.W., Zentgraf, C., Uebelacker, I., Jahns, R., Ertl, G., and Angermann, C.E. 2008. Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study. Eur. J. Heart Fail. 10(12): 1236–1245. doi:10.1016/j.ejheart.2008.09.008.
93. Tabib, A., Loire, R., Chalabreysse, L., Meyronnet, D., Miras, A., Malicier, D., et al. 2003. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation, 108(24): 3000–3005. doi:10.1161/01.CIR.0000108396.65446.21.
94. Tandri, H., Macedo, R., Calkins, H., Marcus, F., Cannom, D., Scheinman, M., et al.; Multidisciplinary Study of Right Ventricular Dysplasia Investigators. 2008.
95. Role of magnetic resonance imaging in arrhythmogenic right ventricular dysplasia: insights from the North American arrhythmogenic right ventricular dysplasia (ARVD/C) study. Am. Heart J. 155(1): 147–153. doi:10.1016/j.ahj. 2007.08.011.
96. Thiene, G. 2014. Sudden cardiac death and cardiovascular pathology: from anatomic theater to double helix. Am. J. Cardiol. 114(12): 1930–1936. doi:10.1016/j.amjcard.2014.09.037.
97. Thorsen, P.J., Berg, A., Hoff, P.I., and Greve, G. 2006. Risk factors for sudden cardiac death related to the long QT syndrome. Tidsskr. Nor. Laegeforen. 126(19): 2515–2519.
98. Vincent, G.M. 2005. The Long QT and Brugada syndromes: causes of unexpected syncope and sudden cardiac death in children and young adults. Semin. Pediatr. Neurol. 12(1): 15–24. doi:10.1016/j.spen.2004.11.008.
99. Wagner, A., Mahrholdt, H., Holly, T.A., Elliott, M.D., Regenfus, M., Parker, M., et al. 2003. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet, 361(9355): 374–379. doi: 10.1016/S0140-6736(03)12389-6.
100. Wolfe, B.A., and Corwin, E.J. 2005. ARVD: a silent killer. Nurse Pract. 30(5): 16–18, 23-17; quiz 27-19. doi:10.1097/00006205-200505000-00007.
101. Yajima, T., and Knowlton, K.U. 2009. Viral myocarditis: from the perspective of the virus. Circulation, 119(19): 2615–2624. doi:10.1161/CIRCULATIONAHA.108. 766022.
102. Yamanaka, O., and Hobbs, R.E. 1990. Coronary artery anomalies in 126,595 patients undergoing coronary arteriography. Cathet. Cardiovasc. Diagn. 21(1): 28–40. doi:10.1002/ccd.1810210110.
103. Zhang, H., Facemire, C.S., Banes, A.J., and Faber, J.E. 2002. Different alphaadrenoceptors mediate migration of vascular smooth muscle cells and adventitial fibroblasts in vitro. Am. J. Physiol. Heart Circ. Physiol. 282(6): H2364–H2370. doi:10.1152/ajpheart.00858.2001.
104. Zhou, Y.H., Wei, X., Lu, J., Ye, X.F., Wu, M.J., Xu, J.F., et al. 2012. Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. PLoS One, 7(2): e31642. doi:10.1371/journal.pone.0031642.
105. Zolk, O., Caroni, P., and Bohm, M. 2000. Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure. Circulation, 101(23): 2674–2677. doi:10.1161/01.CIR.101.23.2674.